EBGLYSS is an FDA-approved drug for treating moderate-to-severe eczema by targeting IL-13, offering relief to patients ...

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...

Therapy for atopic dermatitis is multi-faceted and encompasses ... should be avoided in areas of thinner skin, including the eyelids, face, mucous membranes, genitalia, and intertriginous areas ...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved ...

Skin tags tend to pop up in areas with folds of skin, such as the armpits, groin, or eyelids. They don ... which may help with symptoms of atopic dermatitis and acne. It may also help exfoliate ...

In a 3-year extension of the pivotal trials that provided lebrikizumab with an indication for atopic dermatitis, the response ...

Topline results were announced from a phase 3 trial evaluating rocatinlimab for the treatment of moderate to severe atopic dermatitis.

Discover research presented at EADV 2024 highlighting the significant impact of atopic dermatitis on psychological and social ...

HORIZON Phase 3 trial evaluated rocatinlimab for atopic dermatitis (eczema) in 726 patients. Amgen reported that rocatinlimab outperformed a placebo regarding the severity and extent of the disease.

Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating ...

Atopic Dermatitis, commonly called Eczema, affects millions globally with cases rising in India. Misunderstandings about its ...

Union Therapeutics is looking to advance its PDE4 inhibitor, orismilast, into a Phase III clinical trial for atopic ...